InvestLog
TVRD Tvardi Therapeutics, Inc. logo

TVRD Tvardi Therapeutics, Inc.

Healthcare
$3.57-0.56%ClosedMarket Cap: $33.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.31

P/S

0.00

EV/EBITDA

-0.48

DCF Value

$2.25

FCF Yield

-70.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-64.2%

ROA

-59.8%

ROIC

-200.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-6.8M$—
Q4 null$0.00$-7.3M$—
FY null$0.00$-18.2M$—
Q3 null$0.00$-5.5M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$3.00 - $3.00

0 Strong Buy4 Buy3 Hold0 Sell1 Strong Sell
BarclaysUnderweight
2026-04-20
BarclaysEqual Weight
2026-04-01
BTIGBuy
2026-04-01
Piper SandlerNeutral
2026-04-01
Raymond JamesMarket Perform
2025-10-14

Trading Activity

Insider Trades

View All
O'Brien Stephen Paulofficer: Principal Accounting Officer
SellMon Feb 02
Kauh John Saewook M.D.officer: Chief Medical Officer
SellMon Feb 02
Conn Avi Danielofficer: Chief Financial Officer
SellMon Feb 02
Alibhai Imran Nizamudindirector, officer: Chief Executive Officer
SellMon Feb 02
O'Brien Stephen Paulofficer: Principal Accounting Officer
SellThu Dec 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.30

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Peers

ATNM logoATNMCALC logoCALCELUT logoELUTFGEN logoFGENLTRN logoLTRNLVTX logoLVTXPDSB logoPDSBRVPH logoRVPHTPST logoTPSTXLO logoXLO